Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 179,460Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Asymchem Laboratories (Tianjin) Co., Ltd.

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

Asymchem Laboratories (Tianjin) Co....

Country
The Battery Show
Not Confirmed
arrow

Asymchem Laboratories (Tianjin) Co....

Country
arrow
The Battery Show
Not Confirmed

ADAGRASIB

NDC Package Code : 72015-006

Start Marketing Date : 2022-12-12

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

Looking for 2326521-71-3 / Adagrasib API manufacturers, exporters & distributors?

Adagrasib manufacturers, exporters & distributors 1

43

PharmaCompass offers a list of Adagrasib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Adagrasib manufacturer or Adagrasib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Adagrasib manufacturer or Adagrasib supplier.

PharmaCompass also assists you with knowing the Adagrasib API Price utilized in the formulation of products. Adagrasib API Price is not always fixed or binding as the Adagrasib Price is obtained through a variety of data sources. The Adagrasib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Adagrasib

Synonyms

Mrtx849, 2326521-71-3, Mrtx-849, Adagrasib [usan], Kras g12c inhibitor mrtx849, 8eoo6hqf8y

Cas Number

2326521-71-3

Unique Ingredient Identifier (UNII)

8EOO6HQF8Y

About Adagrasib

Adagrasib is an orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Adagrasib Manufacturers

A Adagrasib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Adagrasib, including repackagers and relabelers. The FDA regulates Adagrasib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Adagrasib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Adagrasib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Adagrasib Suppliers

A Adagrasib supplier is an individual or a company that provides Adagrasib active pharmaceutical ingredient (API) or Adagrasib finished formulations upon request. The Adagrasib suppliers may include Adagrasib API manufacturers, exporters, distributors and traders.

click here to find a list of Adagrasib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Adagrasib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Adagrasib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Adagrasib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Adagrasib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Adagrasib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Adagrasib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Adagrasib suppliers with NDC on PharmaCompass.

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.